Tiziana Life Sciences PLC (LON:TILS) insider Gabriele Cerrone purchased 5,000 shares of the business’s stock in a transaction on Friday, May 31st. The stock was purchased at an average price of GBX 57 ($0.74) per share, for a total transaction of £2,850 ($3,724.03).

Gabriele Cerrone also recently made the following trade(s):

  • On Wednesday, May 1st, Gabriele Cerrone purchased 10,000 shares of Tiziana Life Sciences stock. The stock was purchased at an average price of GBX 60 ($0.78) per share, for a total transaction of £6,000 ($7,840.06).

Shares of LON:TILS opened at GBX 68 ($0.89) on Monday. The company has a market capitalization of $92.80 million and a price-to-earnings ratio of -14.47. The company has a debt-to-equity ratio of 59.12, a quick ratio of 1.03 and a current ratio of 1.08. Tiziana Life Sciences PLC has a 52-week low of GBX 36 ($0.47) and a 52-week high of GBX 148 ($1.93).

COPYRIGHT VIOLATION NOTICE: “Tiziana Life Sciences PLC (TILS) Insider Buys £2,850 in Stock” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/tiziana-life-sciences-plc-tils-insider-buys-2850-in-stock/3029909.html.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.

Read More: How do analysts define an oversold condition?

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.